Comparative Analysis of Human Mesenchymal Stem Cells from Bone Marrow, Adipose Tissue, and Umbilical Cord Blood as Sources of Cell Therapy
Hye Jin Jin,Yun Kyung Bae,Mi-Yeon Kim,Soon-Jae Kwon,Hong Bae Jeon,Soo Jin Choi,Seong Who Kim,Yoon Sun Yang,Wonil Oh,Jong Wook Chang +9 more
607
TL;DR: It is found that recombinant Ang-1 as potential soluble paracrine factor or its small interference RNA (siRNA) was responsible for this beneficial effect in part by preventing inflammation.
read more
Abstract: Various source-derived mesenchymal stem cells (MSCs) have been considered for cell therapeutics in incurable diseases. To characterize MSCs from different sources, we compared human bone marrow (BM), adipose tissue (AT), and umbilical cord blood-derived MSCs (UCB-MSCs) for surface antigen expression, differentiation ability, proliferation capacity, clonality, tolerance for aging, and paracrine activity. Although MSCs from different tissues have similar levels of surface antigen expression, immunosuppressive activity, and differentiation ability, UCB-MSCs had the highest rate of cell proliferation and clonality, and significantly lower expression of p53, p21, and p16, well known markers of senescence. Since paracrine action is the main action of MSCs, we examined the anti-inflammatory activity of each MSC under lipopolysaccharide (LPS)-induced inflammation. Co-culture of UCB-MSCs with LPS-treated rat alveolar macrophage, reduced expression of inflammatory cytokines including interleukin-1α (IL-1α), IL-6, and IL-8 via angiopoietin-1 (Ang-1). Using recombinant Ang-1 as potential soluble paracrine factor or its small interference RNA (siRNA), we found that Ang-1 secretion was responsible for this beneficial effect in part by preventing inflammation. Our results demonstrate that primitive UCB-MSCs have biological advantages in comparison to adult sources, making UCB-MSCs a useful model for clinical applications of cell therapy.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Mesenchymal Stem Cells for Regenerative Medicine.
TL;DR: A brief overview of MSC extraction methods and subsequent potential for differentiation is presented, and a comprehensive overview of their preclinical and clinical applications in regenerative medicine is presented.
909
Mesenchymal stem cells: Cell therapy and regeneration potential.
Christina Brown,Christina McKee,Shreeya Bakshi,Keegan Walker,Eryk Hakman,Sophia Halassy,David Svinarich,Robert Dodds,Chhabi K. Govind,G. Rasul Chaudhry +9 more
TL;DR: The characteristics of MSCs are discussed and it is suggested that the variations in their distinctive features are dependent on the source and method of isolation as well as epigenetic changes during maintenance and growth.
515
Comparative analysis of human mesenchymal stem cells from bone marrow and adipose tissue under xeno-free conditions for cell therapy
Chun Yu Li,Xiao Yun Wu,Jia Bei Tong,Xin Xin Yang,Jing Li Zhao,Quan Fu Zheng,Guo Bin Zhao,Zhi Jie Ma +7 more
TL;DR: Bone marrow-derived MSCs have advantages in osteogenic and chondrogenic differentiation potential and secreted proteins (stem cell-derived factor-1 and hepatocyte growth factor); these biological advantages should be considered systematically when choosing the MSC source for specific clinical application.
Regenerative Capacity of Adipose Derived Stem Cells (ADSCs), Comparison with Mesenchymal Stem Cells (MSCs).
TL;DR: This review analyzed the therapeutic advancement of ADSCs in comparison to bone marrow (BM) and umbilical cord (UC)-mesenchymal stem cells (MSCs) and designed the specific requirements to their best clinical practices and safety.
339
Biodistribution of mesenchymal stem cell-derived extracellular vesicles in a model of acute kidney injury monitored by optical imaging.
Cristina Grange,Marta Tapparo,Stefania Bruno,Devasis Chatterjee,Peter J. Quesenberry,Ciro Tetta,Giovanni Camussi +6 more
TL;DR: It is found that the labeled EVs accumulated specifically in the kidneys of the mice with AKI compared with the healthy controls, indicating that the latter displayed a greater specificity for the injured kidney.